Clinical Trials Browser

Phase 3 × Active not recruiting × Taxes × Clear all

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00433511 2026-05-29

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast

Breast Adenocarcinoma

NCT01081262 2026-05-29

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01167712 2026-05-29

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

NCT04092283 2026-05-29

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

660 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04444921 2026-05-29

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Phase 3 Active not recruiting

205 enrolled

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02488967 2026-05-06

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

782 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05721755 2026-05-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3 Active not recruiting

290 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

450 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06018883 2025-08-07

PTCA199-3

Phase 3 Active not recruiting

100 enrolled

Classical hematology

Anemia

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Phase 3 Active not recruiting

506 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04956692 2024-12-03

MK-3475-A86

Phase 3 Active not recruiting

531 enrolled 18 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung